首页> 外文期刊>Therapeutic advances in psychopharmacology. >The Nursing Assessment of Medication Acceptance: the reliability and validity of a schizophrenia medication adherence scale
【24h】

The Nursing Assessment of Medication Acceptance: the reliability and validity of a schizophrenia medication adherence scale

机译:药物可接受性的护理评估:精神分裂症药物依从性量表的信度和效度

获取原文
获取外文期刊封面目录资料

摘要

Many patients with schizophrenia have low medication adherence. There is, however, no objective assessment scale that can be used by nurses or caregiver specialists. The Nursing Assessment of Medication Acceptance (NAMA) was developed to assess patients’ medication adherence. The aim of this study was to examine the validity and reliability of the NAMA in patients with schizophrenia. A total of 121 Japanese patients with schizophrenia were enrolled. All patients underwent evaluation using the NAMA and the Drug Attitude Inventory (DAI-10). Reliability was investigated using a test-retest method and a parallel-test method. To determine the test-retest reliability of the NAMA, we tested 101 schizophrenia patients twice, with the second assessment 2–4 weeks after the date of the first assessment. For validity verification, standard-related validity and the degree of concordance with the DAI-10 scores were measured. The Cronbach’s alpha value of the NAMA in schizophrenia was 0.88. The test-retest correlation coefficients were all between 0.53–0.74. The total scores and all subscores for the NAMA were significantly correlated, and the NAMA total scores were significantly correlated with the DAI-10 total scores. The NAMA shows good reliability and validity in measuring medication adherence in schizophrenia.
机译:许多精神分裂症患者的药物依从性较低。但是,没有客观的评估量表可供护士或护理人员使用。药物接受的护理评估(NAMA)旨在评估患者对药物的依从性。这项研究的目的是检查NAMA在精神分裂症患者中的有效性和可靠性。共有121名日本精神分裂症患者入组。所有患者均使用NAMA和药物态度清单(DAI-10)进行评估。使用重测方法和并行测试方法研究可靠性。为了确定NAMA的重测信度,我们对101位精神分裂症患者进行了两次测试,第二次评估在第一次评估后的2-4周进行了第二次评估。为了进行有效性验证,测量了与标准相关的有效性以及与DAI-10评分的一致性程度。在精神分裂症中,Cronbach的NAMA的alpha值为0.88。重测相关系数均在0.53至0.74之间。 NAMA的总分和所有分均显着相关,而NAMA的总分与DAI-10的总分显着相关。 NAMA在测量精神分裂症的药物依从性方面显示出良好的可靠性和有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号